Nontuberculous mycobacterial infections due to autoantibodies targeting interferon-γ are an emerging medical problem. However, case finding is hampered due to highly complex diagnostic procedures not available in routine laboratories. We show that QuantiFERON assays can be exploited as a simple screening tool that may facilitate adequate and timely treatment.
Neutralizing autoantibodies targeting interferon gamma (IFN-γ) are increasingly recognized as a major cause for immunodeficiency associated with severe and chronic infections with nontuberculous mycobacteria (NTM) and other opportunistic pathogens [1] . IFN-γ is the critical cytokine for control of NTMs, and high-titer neutralizing antibodies impair IFN-γ-mediated STAT1 phosphorylation required for clearance of these intracellular pathogens [1] . Recent studies gave novel insight into the development of neutralizing anti-IFN-γ antibodies in formerly healthy adults. Human leukocyte antigen (HLA) typing in NTM patients with laboratory-confirmed neutralizing antibodies showed high frequencies of HLA-DRB1*16:02 and HLA-DQB1*05:02 alleles [2] . Genetic predisposition is also supported by the fact that the majority of patients are of Asian descent [3] . A recent report identified the epitope on human IFN-γ targeted by autoantibodies. Binding of patient-derived antibodies to this epitope interferes with IFN-γ-receptor activation [4] . The target motif was shown to be highly homologous to a stretch of an Aspergillus species ribosomal assembly protein, and immunization of rats with a related peptide led to the development of antibodies reacting with human IFN-γ [4] .
While these reports have largely improved our understanding of disease pathogenesis, identification of cases is greatly hampered by a lack of widely available and standardized test formats. However, a timely and proper diagnosis is crucial as adequate care requires both immunosuppressive and antimicrobial treatment. B-cell depletion using therapeutic anti-CD20 antibodies in combination with antimycobacterial therapy was shown to be effective in one case series [5] .
Here we show that the robust QuantiFERON-TB enzymelinked immunosorbent assay (ELISA), which is extensively used for in vitro diagnostics of Mycobacterium tuberculosis infections, can be repurposed for screening of patients with suspected neutralizing IFN-γ antibodies as well as confirmation of the disease.
METHODS
The QuantiFERON-TB test system (Qiagen) uses ELISA to measure IFN-γ levels secreted after antigen stimulation of whole blood. The test contains 3 tubes: a negative control (Nil tube), a positive control (mitogen tube) coated with phytohemagglutinin, a strong nonspecific T-cell stimulant, and a third tube containing tuberculosis-specific antigens. The tuberculosis-test tube was discarded for this study. For screening of suspected IFN-γ neutralizing antibodies, NTM patient whole blood was added to the mitogen tube and the Nil tube and the assay was performed according to the recommendations of the manufacturer. The presence of IFN-γ antibodies was suspected when the mitogen control showed IFN-γ-ELISA values <0.5 IU/mL. This value was corrected for the Nil response using QuantiFERON software, which calculates mitogen minus Nil values. A confirmatory test based on QuantiFERON technology was developed in which mitogen tubes were filled with 1 mL of whole blood from a healthy donor to which 100 µL (1:10 dilution) or 20 µL (1:50 dilution) of NTM patient serum was added (Supplementary Figure 1) . Control serum from a second healthy donor was added to additional mitogen tubes at the same dilutions. Tubes were inverted 10 times and the assay was performed according to the recommendations of the manufacturer. IFN-γ autoantibodies were suspected when the donors' mitogen control showed IFN-γ-ELISA values <0.5 IU/mL. We used blood group 0 donor blood to avoid hemolysis due to ABO incompatibility. The assay performed well with fresh and thawed serum or plasma.
CASE REPORT
In 2011, a 54-year-old human immunodeficiency virus (HIV)-uninfected female patient of Philippine origin presented with pain in her lower legs and shoulders. She complained about night sweats and chills persisting for a total of 4 weeks. Sarcoidosis was suspected, and the patient was treated with azathioprine and corticosteroids. Symptoms improved slightly but after several years, the patient complained about worsening pain in the extremities. Furthermore, she developed soft tissue infections ( Figure 1A ) and lesions in several long bones detected by scintigraphy. Skin biopsies were taken and Mycobacterium parascrofulaceum was isolated from multiple samples. Antimycobacterial treatment was initiated. However, in 2015 the patient developed respiratory insufficiency due to pneumonia, which progressed to acute respiratory distress syndrome with the need for mechanical ventilation. Mycobacterium parascrofulaceum was isolated from tracheal aspirates. A modified combination therapy using amikacin, rifampin, clarithromycin, and moxifloxacin led to improvement and full resolution of pneumonia. However, later in 2015 the patient developed several new M. parascrofulaceum-positive soft tissue infections of the left hip and the breast. Linezolid was therefore added to the regimen but had to be discontinued shortly after due to development of polyneuropathy.
RESULTS
Between 2012 and 2016, a total of 4 QuantiFERON-TB assays were performed on blood samples from our patient. All of them showed suppressed mitogen controls with values <0.5 IU/ mL. Between 2011 and 2013 the patient received corticosteroid treatment, which can be a cause for low values in this control. However, the last 2 tests were performed in the absence of immunosuppressive treatment. These test results were highly suspicious for a deficiency in IFN-γ-dependent immune responses causing chronic and severe NTM infection. To verify the presence of an IFN-γ inhibitory factor in the serum, we performed our novel QuantiFERON-based confirmatory assay in which patient serum is added to the mitogen control tube containing healthy donor blood. At this time-point, the patient did not receive immunosuppressive therapy. Addition of 100 µL or 20 µL of patient serum led to full suppression of IFN-γ detection in mitogen samples. Values were comparable to the Nil control ( Figure 1B ). Healthy donor serum had no effect on the performance of the mitogen control in this assay ( Figure  1B) . These results clearly point toward the presence of neutralizing IFN-γ antibodies in patient serum. Additional assays ruled out an IFN-γ receptor defect using fluorescence-activated cell sorting (FACS) analysis on CD14 gated patient monocytes performed as described recently (Supplementary Figure 2) [6] . Stimulation of isolated monocytes with IFN-γ led to CD64 upregulation indicating normal IFN-γ signaling (Supplementary Figure 3) . Finally, IFN-γ antibodies in patient serum were titrated by performing an IFN-γ ELISA using recombinant anti-IFN-γ and patient serum at different concentrations. Serum dilutions as high as 1:2700 fully blocked IFN-γ detection in this test ( Figure 1C ). These assays confirmed our QuantiFERON-based results and led to the diagnosis of IFN-γ neutralizing autoantibodies.
To corroborate our results, we examined 3 additional serum samples of patients with confirmed IFN-γ neutralizing autoantibodies. One of these samples was obtained from a recently published case with severe disseminated Mycobacterium avium intracellulare infection due to autoantibodies targeting IFN-γ in a white patient [7] . Biobanked pretreatment patient serum was examined in our QuantiFERON-based IFN-γ inhibition assay. The mitogen control values of healthy donor blood were potently suppressed, similar to findings made for the patient described in our case report (Supplementary Figure 4) . Additional healthy donor control serum samples had no or little effect on mitogen values. Of note, retrospective analysis of the white patient's medical history also revealed negative mitogen controls in QuantiFERON assays performed during patient workup in 2014.
DISCUSSION
There is a lack of widely available and standardized laboratory tests for diagnosing adult-onset IFN-γ neutralizing antibodies. Recent studies have used a whole range of in-house laboratory assays such as Western blot, FACS analysis, particle-based assays, and ELISA for antibody detection in patient blood samples [1, [7] [8] [9] . These tests were established in a few highly specialized immunological laboratories.
QuantiFERON has become a worldwide standard for diagnosis of latent tuberculosis. The assay is widely available in Asian countries where severe NTM infections due to neutralizing IFN-γ antibodies are most prevalent. We have shown that the mitogen control test tube of QuantiFERON can be easily repurposed for detection of IFN-γ neutralizing serum activity. Our method is based on abrogation of the mitogen response in samples containing neutralizing antibodies. Negative mitogen controls in adults are frequent and several causes have been identified. Predominant among these are immunosuppression caused by HIV infection with low CD4-positive T-cell counts and corticosteroid therapy [10] . Another major cause for low values in mitogen controls can be improper handling of blood samples. Once inhibitory factors can be ruled out, a repeatedly negative mitogen control in a patient with adult-onset immunosuppression is suspicious for impaired IFN-γ signaling due to neutralizing IFN-γ antibodies. Two other case reports of NTM patients suffering from neutralizing IFN-γ autoantibodies also described negative mitogen controls [11, 12] . Though it was not mentioned whether these patients were receiving immunosuppressive treatment at the time the assay was performed, our findings together with published reports indicate that extremely low values in QuantiFERON mitogen controls are a universal feature of the disease. Importantly, our confirmatory assay based on NTM-patient serum driven mitogen control inhibition of healthy donor blood is fully independent of confounding factors such as long-term corticosteroid therapy. In conclusion, our findings may provide an excellent and widely available diagnostic tool that allows screening for neutralizing IFN-γ antibodies, eventually leading to rapid and adequate care. Once tested positive in the QuantiFERON-based assays described here, patient samples should be forwarded to immunology reference laboratories for in-depth analysis of IFN-γ signaling if available. Of note, retrospective analysis of QuantiFERON mitogen test tube results may identify additional cases of neutralizing IFN-γ antibodies. Before broad application of the novel QuantiFERON-based IFN-γ inhibition assay, larger prospective studies should be performed to answer important questions regarding sensitivity and specificity, as well as false-positive results due to nonneutralizing low-titer anti-IFN-γ autoantibodies, which frequently occur in healthy patients. Clinical trials are therefore warranted.
